Capping Pascal Soriot’s big turnaround, the analysts at Cowen say AstraZeneca is poised for a stellar year
Big Pharmas typically don’t get a lot of respect for R&D efforts. Their ROI is bad on a massive annual bill, there’s too much late …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
